Implantable Insulin Pump Market

Executive Summary

Implantable Insulin Pump Market was valued at US $10.38 billion in 2021 and is projected to grow at 7.31% CAGR over the forecast period to reach US $15.85 billion by 2027. Implantable Insulin Pump Market represented US $1.37 billion opportunity over 2019-2021 and estimated to create US $5.47 billion opportunity in 2027 over 2021.

Implantable Insulin Pump from Consainsights analyses the Implantable Insulin Pump Market in the Life Sciences industry over the forecast period to 2027.

Implantable Insulin Pump research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Implantable Insulin Pump segmentation includes Type, End User, Region and Geography.

Based on the Type, the Implantable Insulin Pump analysis covers CLOSED-LOOP INSULIN PUMP, OPEN-LOOP INSULIN PUMP.

In Type segment, CLOSED-LOOP INSULIN PUMP segment has highest cagr growth of 6.47%.

Based on the End User, the Implantable Insulin Pump analysis covers HOSPITALS, INDIVIDUALS (SELF-MEDICATION).

In End User segment, HOSPITALS segment has highest cagr growth of 6.47%.

Based on the Region, the Implantable Insulin Pump analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 6.47%.

Based on the region, the Implantable Insulin Pump analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include MEDTRONIC, INSULET CORPORATION, F. HOFFMANN LA ROCHE LTD., ANIMAS CORPORATION, SOOIL DEVELOPMENTS CO., LTD., JOHNSON & JOHNSON, TANDEM DIABETES CARE, INC., AETNA INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, CLOSED-LOOP INSULIN PUMP segment has the highest revenue of US $5.44 billion and is expected to grow at CAGR of 6.47% by 2027 CLOSED-LOOP INSULIN PUMP segment has highest cagr growth of 6.47%.

CLOSED-LOOP INSULIN PUMP

CLOSED-LOOP INSULIN PUMP segment was valued at US $4.73 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $8.31 billion by 2027. CLOSED-LOOP INSULIN PUMP segment represented US $0.72 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.

OPEN-LOOP INSULIN PUMP

OPEN-LOOP INSULIN PUMP segment was valued at US $4.28 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $7.53 billion by 2027. OPEN-LOOP INSULIN PUMP segment represented US $0.65 billion opportunity over 2019-2021 and estimated to create US $2.60 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $7.29 billion and is expected to grow at CAGR of 6.47% by 2027 HOSPITALS segment has highest cagr growth of 6.47%.

HOSPITALS

HOSPITALS segment was valued at US $6.33 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $11.13 billion by 2027. HOSPITALS segment represented US $0.96 billion opportunity over 2019-2021 and estimated to create US $3.84 billion opportunity in 2027 over 2021.

INDIVIDUALS (SELF-MEDICATION)

INDIVIDUALS (SELF-MEDICATION) segment was valued at US $2.68 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $4.71 billion by 2027. INDIVIDUALS (SELF-MEDICATION) segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $1.63 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $6.50 billion and is expected to grow at CAGR of 6.47% by 2027 EUROPE segment has highest cagr growth of 6.47%.

EUROPE

EUROPE segment was valued at US $5.64 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $9.93 billion by 2027. EUROPE segment represented US $0.86 billion opportunity over 2019-2021 and estimated to create US $3.43 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $1.70 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $3.00 billion by 2027. ASIA-PACIFIC segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.03 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $1.66 billion in 2019 and is projected to grow at 6.47% CAGR over the forecast period to reach US $2.92 billion by 2027. LAMEA segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $1.01 billion opportunity in 2027 over 2021.